Posts

Opiant Pharmaceuticals, Inc. Announces Listing on the Nasdaq Capital Market

Aug 28, 2017
OTC Disclosure & News Service

SANTA MONICA, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that its shares of common stock were approved for listing on the Nasdaq Capital Market (“Nasdaq”). Trading on Nasdaq under the symbol “OPNT” is expected to commence on August 29, 2017.

“Our listing on Nasdaq represents a major corporate milestone for Opiant as we continue to progress into a leading player in the treatment of addictions,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “We believe that trading on Nasdaq will expand our visibility, broaden and diversify our stockholder base, provide better liquidity and ultimately contribute to our ability to increase stockholder value.”

Opiant’s common stock, which has been trading on the OTCQB Marketplace (the “OTCQB”) since April 2007, will continue to trade on the OTCQB until the market closes on August 28, 2017.

About Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Limited. For more information please visit: www.opiant.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by Opiant or any other person that the objectives and plans of Opiant will be achieved in any specified time frame, if at all. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

CONTACT INFORMATION:

Corporate Contact:
Investor.relations@opiant.com

Investors:
Sam Martin
Argot Partners
sam@argotpartners.com
212-600-1902
Primary Logo

Copyright © 2017 GlobeNewswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Opiant CEO Roger Crystal Appears on Fox News Channel to Discuss the Opioid Crisis Being Declared a National Emergency

Aug 14, 2017
OTC Disclosure & News Service

SANTA MONICA, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that Roger Crystal, M.D., Chief Executive Officer of Opiant, was interviewed on Friday, August 11, on Fox News Channel. The segment, which appeared on “The Story with Martha MacCallum,” discussed President Trump’s declaration of a national emergency over the opioid epidemic in America. The discussion focused on the potential effects of declaring a national emergency, including wider access to NARCAN® Nasal Spray and increased funding for new products. Opiant’s pipeline includes a heroin vaccine, as well as products in development for both Opioid Use Disorder and Alcohol Use Disorder.

“The Story with Martha MacCallum” airs weeknights at 7:00pm Eastern on Fox News Channel and keeps viewers up-to-date on the critical decisions, political maneuvers and key developments coming out of Washington, D.C. Please click here to view the segment.

About Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders. NIDA, a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Limited. For more information please visit: www.opiant.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by Opiant or any other person that the objectives and plans of Opiant will be achieved in any specified time frame, if at all. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

CONTACT INFORMATION:

Corporate Contact:
Investor.relations@opiant.com

Investors:
Sam Martin
Argot Partners
sam@argotpartners.com
212-600-1902
Primary Logo

Copyright © 2017 GlobeNewswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization

Aug 10, 2017
OTC Disclosure & News Service

SANTA MONICA, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that the Company has received an additional $3.75 million payment from SWK Funding LLC, an affiliate of SWK Holdings Corporation (“SWK”), as specified in the previously announced royalty monetization agreement with SWK. In December 2016, SWK acquired certain of the NARCAN® Nasal Spray (“NARCAN”) royalties and milestone payments for up to $17.5 million. Opiant received an initial $13.7 million net payment from SWK at the December 2016 closing, and this additional $3.75 million is based on the achievement of at least $25 million of cumulative net sales of NARCAN during two consecutive quarters in the first half of 2017. Pursuant to the royalty monetization agreement, after SWK has received an aggregate of $26.25 million in royalties and milestones, Opiant will receive at least 90% of future NARCAN royalties and milestone payments.

“We are pleased to report this additional payment from SWK,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “NARCAN has a critical role in addressing the unmet need of the current opioid epidemic. Opiant is committed to developing pharmacological treatments to address a broad range of addictions. This additional payment allows Opiant to progress its pipeline, including advancing OPNT002, Opiant’s nasal naltrexone treatment for Alcohol Use Disorder.”

NARCAN is the only FDA-approved naloxone nasal spray for the emergency treatment of known or suspected opioid overdose. Opiant licensed NARCAN to Adapt Pharma Operations Limited (“Adapt Pharma”) and, pursuant to the terms of such license agreement, could receive total potential milestone payments of more than $55 million and up to double-digit royalties on net sales. Adapt Pharma launched NARCAN in the United States and Canada in 2016.

About Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Operations Limited. For more information please visit: www.opiant.com.

About SWK Holdings Corporation

SWK Holdings Corporation (“SWK”) is a specialized finance company with a focus on the global healthcare sector. SWK partners with ethical product marketers and royalty holders to provide flexible financing solutions at an attractive cost of capital to create long-term value for both SWK’s business partners and its investors. SWK believes its financing structures achieve an optimal partnership for companies, institutions and inventors seeking capital for expansion or capital and estate planning by allowing its partners to monetize future cash flow with minimal dilution to their equity stakes. Additional information on the life science finance market is available on the Company’s website at www.swkhold.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by Opiant or any other person that the objectives and plans of Opiant will be achieved in any specified time frame, if at all. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

CONTACT INFORMATION:

Corporate Contact:
Investor.relations@opiant.com

Investors:
Sam Martin
Argot Partners
sam@argotpartners.com
212-600-1902
Primary Logo

Copyright © 2017 GlobeNewswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent

Aug 04, 2017
OTC Disclosure & News Service

SANTA MONICA, Calif., Aug. 04, 2017 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced that its most recently issued U.S. Patent, No. 9,707,226, covering methods of use for the two-milligram (2mg) formulation of NARCAN® Nasal Spray (“NARCAN”), is now listed in the U.S. Food and Drug Administration (FDA) publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

“We are pleased with this new patent issuance and subsequent Orange Book listing. We now have six Orange Book-listed patents for NARCAN, and remain encouraged by our solid intellectual property position and enhanced product exclusivity,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “This latest patent also has the potential to be relevant to other products in development by Opiant.”

U.S. Patent No. 9,707,226 claims nasal spray formulations and methods of treatment covering the 2mg dose of NARCAN, which was approved by the FDA in January 2017. The patent provides for drug products adapted for nasal delivery via a pre-primed device filled with a pharmaceutical composition containing an opioid receptor antagonist. The patent also provides for methods of treating opioid overdose or its symptoms with the 2mg formulation of NARCAN. An Orange Book listing requires an Abbreviated New Drug Application (ANDA) applicant seeking FDA approval of a generic version of NARCAN to notify the Company and its partner, Adapt Pharma Limited, before it can obtain FDA approval. This would be subject to a 30-month stay of marketing approval and potentially longer if such notification occurs and a patent infringement suit is successful.

About Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders. NIDA, a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Limited. For more information please visit: www.opiant.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by Opiant or any other person that the objectives and plans of Opiant will be achieved in any specified time frame, if at all. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

CONTACT INFORMATION:

Corporate Contact:
Investor.relations@opiant.com

Investors:
Sam Martin
Argot Partners
sam@argotpartners.com
212-600-1902
Primary Logo

Copyright © 2017 GlobeNewswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

FERN Announces Development of Off-Grid Power Storage Device

FOUNTAIN HILLS, Ariz., Aug. 1, 2017 /PRNewswire/ — Fernhill Corporation (OTC PINK: FERN) is pleased to announce the recent development of a new power generation and storage prototype.

The first design in a newly launched suite of products will be the “P72” short for “Prototype 72”. After a major disaster, the first 72 hours can be the most challenging for families that are not adequately prepared. The “P72” product is designed to provide temporary off grid power backup for an entire family at this critical time. When grid power goes off-line by or during a natural disaster, the “P72” is designed to provide power, lighting and charging for the most essential equipment. We understand that emergency communication is equally as important as having a readily available power source. The “P72” device will provide adequate power for lighting, emergency equipment, cellular phones and emergency broadcast devices.

The extremely durable “P72” design will also allow for the device to be used as a recreational family product. The portability of the “P72” product allows for quick deployment and will give users the ability to have immediate off grid power generation. High powered outputs, multiple methods of charging and large battery capacities make the “P72” a perfect alternative to traditional gas-powered generation. The “P72” device will also integrate a design specific for export to several key countries in 2018. These selected countries will then have a viable solution where grid stability and affordable power options are not adequately available.

Currently, the developed working prototypes are in the process of integrating several product improvements to ensure retail acceptance. The commercialization of the “P72” product line is now in the sights of the company moving forward. Production in an Arizona facility is anticipated to commence in the 4th quarter of 2017.

The “P72” device will be product branded in the future and packaged as a solution with a “Made in the USA” label. Our goal is to provide homes in and outside of the United States with a readily available and stable power supply.

About Fernhill Corporation

Fernhill Corporation is a holding company focused in the energy and technology sector. Incorporated in Nevada with operations in North America, Fernhill Corporation is focused on acquisitions and or partnerships in energy based sector businesses.

Safe Harbor Act: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

View original content:http://www.prnewswire.com/news-releases/fern-announces-development-of-off-grid-power-storage-device-300497327.html

SOURCE Fernhill Corporation

Copyright © 2017 PR Newswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Opiant CEO Roger Crystal Appears on Fox & Friends

Jul 27, 2017
OTC Disclosure & News Service

SANTA MONICA, Calif., July 27, 2017 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced that Roger Crystal, M.D., Chief Executive Officer of Opiant, was featured this morning on Fox & Friends. The recurring segment, titled “Addiction in America,” details various aspects of the addiction crisis in the United States. Dr. Crystal was interviewed by Fox & Friends host Ainsley Earhardt. The focus of the discussion was the national opioid epidemic, what Opiant is doing to help and the advantages of NARCAN® Nasal Spray. Additionally, Dr. Crystal discussed Opiant’s product pipeline, which includes products in development for both Alcohol Use Disorder and Opioid Use Disorder.

Fox & Friends is a weekday morning news show hosted by Fox News Channel that features hosts Ainsley Earhardt, Steve Doocy and Brain Kilmeade. Regular features include medical contributors, reports from entertainment correspondents and interviews with newsmakers. Please click here to view the segment.

About Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders. NIDA, a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Limited. For more information please visit: www.opiant.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by Opiant or any other person that the objectives and plans of Opiant will be achieved in any specified time frame, if at all. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

CONTACT INFORMATION:

Corporate Contact:

Investor.relations@opiant.com

Investors:

Sam Martin
Argot Partners
sam@argotpartners.com
212-600-1902
Primary Logo

Copyright © 2017 GlobeNewswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Opiant CEO Roger Crystal Appears on Fox Business Network

Jul 26, 2017
OTC Disclosure & News Service

SANTA MONICA, Calif., July 26, 2017 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced that Roger Crystal, M.D., Chief Executive Officer of Opiant, was interviewed by Maria Bartiromo on Fox Business Network’s “Mornings with Maria” this morning. The focus of the discussion was the national opioid epidemic and the advantages of NARCAN® Nasal Spray, as well as Opiant’s product pipeline, which includes products under development for both Alcohol Use Disorder and Opioid Use Disorder.

“Mornings with Maria” features anchor Maria Bartiromo alongside a roundtable of rotating industry titans and economic experts discussing the major news and themes driving the business day and the market moves. Please click here to view the segment.

About Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders. NIDA, a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Limited. For more information please visit: www.opiant.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by Opiant or any other person that the objectives and plans of Opiant will be achieved in any specified time frame, if at all. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

CONTACT INFORMATION:

Corporate Contact:

Investor.relations@opiant.com

Investors:

Sam Martin
Argot Partners
sam@argotpartners.com
212-600-1902
Primary Logo

Copyright © 2017 GlobeNewswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

KSIX Completes Much Anticipated Agreement with True Wireless

LAS VEGAS, NV — (Marketwired) — 07/24/17 — KSIX Media Holdings, Inc. (OTCBB: KSIX) “The Company”, announced the signed equity agreement with True Wireless. The company will immediately begin managing True Wireless adding over $1.1 million dollars to the company’s monthly revenue.

Under the agreement, control of the company has shifted to Brian Cox. Cox brings an experienced team of blue chip accounting, legal, sales and operations teams. Cox noted, “The first step in my plan is to get KSIX Holdings’ combined revenues to over $2 Million a month. Operationally, we will be reorganizing to increase the company’s efficiency. We will synergize the KSIX-TRUE team so everyone has a specialized role with laser focus and a burning desire to grow the company.”

The company will be filing to change to a telecommunications classification. Cox stated, “I think the telecom sector will be one of the fastest growth sectors due to mobile wallets, blockchain technology and digital crypto-currency. This will create more dependence on our smartphones and connectivity. Look at the ICOs and what is going on around the world. I have already hired a lead programmer to help develop our digital stratagem worldwide.”

Cox also promised to catch the company up on its filings and keep them current, noting, “I believe you conduct yourself today, how you would like to be tomorrow, which is why KSIX will operate as if it were a blue chip company starting now.”

“We also want to connect with our shareholders by creating an environment where people can invest not only in the analytics of the company, but get to know us and be involved in our growth. To that end we are creating a company blog, newsletter, videos with question and answer sessions to keep our shareholders updated on our progress and direction. This momentum is now action based and it is no longer a story of what we will do……but what we are doing.”

For any questions regarding the agreement, please email invest@gotruewireless.com or call 901-687-7895.

ABOUT KSIX MEDIA HOLDINGS
KSIX Media Holdings, Inc. (OTCBB: KSIX), a Las Vegas based company, helps companies make more profit by utilizing proprietary software and intellectual property to leverage social media marketing to help grow the online presence and sales of clients while reducing cost per acquisition. KSIX also provides perform based traffic and sales via ad network distribution.

ABOUT TRUE WIRELESS, LLC
True Wireless LLC, an Oklahoma based company, is a nationwide wireless carrier with the ability to provide service over all 4 major USA wireless backbones. True is a licensed eligible telecommunications carrier (OK, AR, MD, RI and TX) providing discounted and subsidized wireless (cell phone) and broadband service through the National Broadband Program.

About Brian Cox
Brian Cox has been the majority owner and CEO of True Wireless since January, 2011. True Wireless has been a leader and innovator in the lifeline and now national broadband initiative space. Mr. Cox got his start in telecom in 2004 when he founded his first telephone company. Through organic growth and acquisition, he grew the company to the largest prepaid home phone company in the country and sold it in late 2009.

Mr. Cox is a minority partner, investor and or stakeholder in several other technology companies including telecom, wireless and network transactions using blockchain programming with digital currencies. Mr. Cox is also passionate about the growth of his foundation for the advancement of lower income children based in Memphis, TN.

Mr. Cox has a proven track record of not only success but winning. Many aspects of his leadership style are contributed to what he learned on the football field while earning Team Captain and All-Conference honors at Murray State University while majoring in Economics.

FORWARD LOOKING STATEMENTS
Certain statements in this release, other than statements of historical fact, may include forward-looking information that involves various risks and uncertainties. There can be no assurance that such forward-looking statements will prove to be accurate. Actual result and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change, other than as required pursuant to applicable securities laws.

KSIX Media Holdings, Inc.
invest@gotruewireless.com
901-687-7895

Source: KSIX Media Holdings, Inc.

Opiant Pharmaceuticals, Inc. Announces Phase I Data for OPNT002 in Development for the Treatment of Alcohol Use Disorder

Jul 19, 2017
OTC Disclosure & News Service

Intravail® Increased the Rate of Absorption of Intranasal Naltrexone

No Serious Adverse Events or Evidence of Nasal Irritation

Contract Signed with Renaissance to Advance Product Development

SANTA MONICA, Calif., July 19, 2017 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced results from a Phase 1 trial of OPNT002, an intranasally dosed (IN) formulation of the opioid antagonist naltrexone hydrochloride (naltrexone), in development for the treatment of Alcohol Use Disorder (AUD). This study was conducted under a clinical trial agreement between Opiant and the National Institute of Drug Abuse (NIDA), a division of the National Institutes of Health (NIH). The study examined the effects of Intravail®, an absorption enhancer, on the pharmacokinetic properties of IN naltrexone in healthy volunteers. The trial also assessed the safety of IN naltrexone, particularly with respect to nasal irritation. Opiant has also signed an agreement with Renaissance to initiate work on the product development.

Some notable Phase 1 findings include:

Intravail®, recently licensed by Opiant from Aegis Therapeutics, increased the maximal plasma concentrations (Cmax) of IN naltrexone by almost three-fold compared to IN naltrexone alone.

The addition of Intravail® significantly accelerated the time (Tmax) to reach maximum observed plasma concentrations of naltrexone, from 30 minutes to 10 minutes.

No safety or tolerability concerns were identified; there was no evidence of nasal irritation.
“Naltrexone is a well-known treatment for AUD, and this study sheds new light on the potential clinical benefits of combining intranasally administered naltrexone with Intravail®,” said Stephanie Samples O’Malley, PhD, Professor of Psychiatry; Director, Division of Substance Abuse Research in Psychiatry; Deputy Chair, Clinical Research at Yale School of Medicine and consultant to Opiant Pharmaceuticals. “Although the sample size of this study is small, these data suggest that pairing Intravail® with IN naltrexone enhances the effect of the drug which could support the development of a new method for treating AUD.”

Phil Skolnick, Ph.D., D.Sc. (hon.), Chief Scientific Officer at Opiant Pharmaceuticals, Inc. added, “We are very excited by the observed changes in the pharmacokinetic properties of intranasal naltrexone when combined with Intravail®, particularly the ability of Intravail® to reduce the time needed to reach maximum plasma concentrations, which implies a more rapid onset of action. Although additional clinical work is required, the ability to rapidly deliver an intranasal dose of naltrexone on an ‘as needed’ basis has the potential to offer patients a much-needed innovation in the treatment of AUD.”

Study Design:
This study was an in-patient, open-label, four-period, four-treatment, one-sequence, crossover design. Subjects were 14 healthy male and female volunteers ages 18 to 55 with no pre-existing nasal abnormalities. Each subject received four naltrexone treatments during the four dosing periods.

Summary of topline data:
When the IN naltrexone formulation included Intravail®, the maximum plasma concentration (Cmax) increased 3-fold and the median time to reach the maximum observed plasma concentration (Tmax) decreased from 30 minutes to 10 minutes. The median time to reach maximum observed plasma concentration of IN naltrexone administered with Intravail was also more rapid than an intramuscular injection. Absorption of naltrexone after oral administration of 50 mg was slower than either IN or IM administration at earlier time points.

All treatments were considered safe and well tolerated, with no severe or serious adverse events (AEs) observed.

Opiant has signed a contract manufacturing agreement with Renaissance (Lakewood, NJ) to begin work on optimizing an IN naltrexone formulation for Phase II studies. “Signing this agreement represents significant progress towards advancing this pipeline,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “We worked with Renaissance (previously DPT) for commercial manufacturing of the NARCAN Nasal Spray, so we have a high degree of confidence in their ability to deliver.”

About Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders. NIDA, a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Limited. For more information please visit: www.opiant.com.

About Intravail®

Intravail® drug delivery technology facilitates non-invasive delivery of a broad range of non-peptide and peptide drugs, as well as non-invasive delivery of protein drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, with high bioavailability and increased speed of absorption.

About Naltrexone

Naltrexone is a high affinity opioid receptor antagonist. Initially approved by the FDA to treat opioid use disorders, subsequent clinical studies led to its approval to treat AUDs in 1994. Both clinical and preclinical studies have demonstrated that that alcohol consumption triggers the release of endorphins and enkephalins, naturally occurring opioid like peptides. By blocking the effects of these molecules at opioid receptors, naltrexone reduces craving for alcohol as well as the amount of alcohol consumed.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by Opiant or any other person that the objectives and plans of Opiant will be achieved in any specified time frame, if at all. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

CONTACT INFORMATION:

Corporate Contact:
Investor.relations@opiant.com

Investors:
Sam Martin
Argot Partners
sam@argotpartners.com
212-600-1902
Primary Logo

Copyright © 2017 GlobeNewswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

KSIX Media Holdings Announces Shareholder Update-Carter Matzinger, KSIX CEO updates shareholders on True Wireless Merger Transaction and Ongoing Operations

LAS VEGAS, NV — (Marketwired) — 07/17/17 — KSIX Media Holdings, Inc. (OTCBB: KSIX), a diversified media and internet company headquartered in Las Vegas, announce today a shareholder update.

Dear Shareholders:

I am excited to communicate that KSIX has made significant progress in the merger transaction with True Wireless and growing our core media business. I am also pleased to report, as notified in a recent 8k, we have selected new auditors in an effort to expedite all of our OTC filing requirements. This past Friday, we published a pre 14C to increase the authorized shares from 100m to 500m. This is a necessary step in our strategic plan for near future expansion and acquisitions.

Regarding the True Wireless acquisition, True Wireless CEO Brian Cox stated: “I feel we are literally just a few days away from having a signed equity contract. I have already engaged Roderfer, Moss and Co, PLLC to complete the precondition 2 year audits for closing. From an industry standpoint, the FCC recently posted an increased budget for the lifeline/broadband program at $2.2B for 2018. Internally, True Wireless was just under $1.2M revenue for June. There is palpable energy and momentum within our team and we are ready for the tasks ahead.”

As KSIX continues to grow, to better engage and inform our shareholders regarding our expansion activities, we are setting up new correspondence through email, video and social updates. All communication will be readily available on the Ksixmedia.com website so please check it often and sign up for instant alerts, updates and video events.

Sincerely,

Carter Matzinger, CEO KSIX Media Holdings

ABOUT KSIX MEDIA HOLDINGS KSIX Media Holdings, Inc. (OTCBB: KSIX) KSIX, a Las Vegas based company, has two operating divisions, DigitizeIQ and KSIX Media, Inc. DigitizeIQ provides digital advertising utilizing proprietary technology and intellectual properties designed to create new revenue streams and increase measurable audiences for clients. KSIX Media provides performance-based marketing via an advertising network that drives traffic and sales. KSIX manages offer tracking, reporting, and distribution on the third-party platform.

ABOUT TRUE WIRELESS, LLC True Wireless LLC, an Oklahoma based company, is a nationwide wireless carrier with the ability to provide service over all 4 major USA wireless backbones. True is a licensed eligible telecommunications carrier (OK, AR, MD, RI and TX) providing discounted and subsidized wireless (cell phone) and broadband service through the National Broadband Program.

FORWARD LOOKING STATEMENTS Certain statements in this release, other than statements of historical fact, may include forward-looking information that involves various risks and uncertainties. There can be no assurance that such forward-looking statements will prove to be accurate. Actual result and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change, other than as required pursuant to applicable securities laws.

Contact Information
KSIX Media Holdings, Inc
info@ksix.com
Source: KSIX Media Holdings, Inc

Investor Contact
OmniVance Advisors
PR@ksix.com
858-381-5740

Source: KSIX Media Holdings, Inc.